ARCT
Price
$7.45Alerts
Change
-$0.15 (-1.97%)
Updated
Nov 20 closing price
Capitalization
294.18M
Intraday BUY SELL Signals
MRVI
Price
$6.98Alerts
Change
-$0.21 (-2.92%)
Updated
Nov 20 closing price
Capitalization
1.12B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs MRVI

ARCT vs MRVI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARCT vs. MRVI commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and MRVI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARCT with price predictions
Nov 20, 2026

ARCT sees MACD Histogram just turned negative

ARCT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ARCT entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ARCT's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.712) is normal, around the industry mean (3.596). P/E Ratio (-3.108) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (443.347).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MRVI with price predictions
Nov 20, 2026

MRVI in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 27, 2026

MRVI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 32 similar instances where the stock broke above the upper band. In 30 of the 32 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRVI as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for MRVI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

MRVI moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for MRVI crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +14.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.475) is normal, around the industry mean (3.596). P/E Ratio (-14.189) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARCT vs MRVI: Fundamental Ratings
ARCT
MRVI
OUTLOOK RATING
1..100
6169
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
9658
SEASONALITY SCORE
1..100
507

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRVI's Valuation (15) in the null industry is in the same range as ARCT (32) in the Pharmaceuticals Major industry. This means that MRVI’s stock grew similarly to ARCT’s over the last 12 months.

MRVI's Profit vs Risk Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that MRVI’s stock grew similarly to ARCT’s over the last 12 months.

MRVI's SMR Rating (97) in the null industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that MRVI’s stock grew similarly to ARCT’s over the last 12 months.

MRVI's Price Growth Rating (37) in the null industry is in the same range as ARCT (64) in the Pharmaceuticals Major industry. This means that MRVI’s stock grew similarly to ARCT’s over the last 12 months.

MRVI's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that MRVI’s stock grew somewhat faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTMRVI
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 18 days ago
82%
Bullish Trend 13 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (ARCT: $7.45 vs. MRVI: $6.98)
Brand notoriety: ARCT and MRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 71% vs. MRVI: 76%
Market capitalization -- ARCT: $294.18M vs. MRVI: $1.12B
ARCT [@Biotechnology] is valued at $294.18M. MRVI’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 1 FA rating(s) are green while MRVI’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 1 green, 4 red.
  • MRVI’s FA Score: 1 green, 4 red.
According to our system of comparison, MRVI is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while MRVI’s TA Score has 3 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 5 bearish.
  • MRVI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than MRVI.

Price Growth

ARCT (@Biotechnology) experienced а -10.89% price change this week, while MRVI (@Biotechnology) price change was -7.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

MRVI is expected to report earnings on Feb 24, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-1.97%
CRSP - ARCT
54%
Loosely correlated
+0.44%
BCYC - ARCT
52%
Loosely correlated
-4.92%
NVAX - ARCT
51%
Loosely correlated
-3.24%
EDIT - ARCT
51%
Loosely correlated
-4.09%
PRME - ARCT
50%
Loosely correlated
-7.55%
More

MRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with TWST. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRVI
1D Price
Change %
MRVI100%
-2.92%
TWST - MRVI
50%
Loosely correlated
-7.44%
MRNA - MRVI
47%
Loosely correlated
-2.17%
RXRX - MRVI
46%
Loosely correlated
-9.93%
ARCT - MRVI
43%
Loosely correlated
-1.97%
BNTX - MRVI
43%
Loosely correlated
-0.52%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MINN21.470.07
+0.33%
Mairs & Power Minnesota Municipal Bond ETF (MINN)
VALQ67.98-0.89
-1.29%
American Century U.S. Quality Value ETF (VALQ)
IQLT46.80-1.10
-2.30%
iShares MSCI Intl Quality Factor ETF (IQLT)
FXR82.84-2.05
-2.41%
First Trust Industrials/Producer Durables AlphaDEX Fund (FXR)
TTDU11.14-2.11
-15.92%
T-REX 2X Long TTD Daily Target ETF (TTDU)